EU/3/18/2042:

Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene

Table of contents

Overview

On 31 July 2018, orphan designation (EU/3/18/2042) was granted by the European Commission to MeiraGTx UK II Limited, United Kingdom, for adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene for the treatment of achromatopsia.

The sponsorship was transferred to MeiraGTx B.V., The Netherlands in May 2019.

The sponsor’s address was updated in July 2021.

Key facts

Active substance
Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene
Intented use
Treatment of achromatopsia
Date of designation
31/07/2018
Orphan designation status
Positive
EU designation number
EU/3/18/2042

Sponsor's contact details

MeiraGTx B.V.
Paalbergweg 2-4
Amsterdam 
1105 AG
Noord-Holland
Netherlands
tel: +31858000860
e-mail: Janneke.Meulenberg@meiragtx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating